Jump to ContentJump to Main Navigation
Show Summary Details
More options …

Drug Metabolism and Personalized Therapy

Official journal of the European Society of Pharmacogenomics and Personalised Therapy

Editor-in-Chief: Llerena, Adrián

Editorial Board: Benjeddou, Mongi / Chen, Bing / Hubacek, Jaroslav A. / Ingelman-Sundberg, Magnus / Manolopoulos, Vangelis G. / Marc, Janja / Meyer, Urs A. / Nair, Sujit / Nofziger, Charity / Peiro, Ana / Simmaco, Maurizio / Schaik, Ron / Shin, Jae-Gook / Visvikis-Siest, Sophie

CiteScore 2018: 1.01

SCImago Journal Rank (SJR) 2018: 0.277
Source Normalized Impact per Paper (SNIP) 2018: 0.446

See all formats and pricing
More options …
Volume 28, Issue 2


Fluorescence spectroscopic study for competitive binding of antidiabetic drugs and endogenous substances on serum albumin

Neelam Seedher / Mamta Kanojia
Published Online: 2013-04-04 | DOI: https://doi.org/10.1515/dmdi-2012-0044


Background: The hypoglycemic effect of antidiabetic drugs varies with change in the level of endogenous substances in the body in diseased states largely due to alteration in drug-serum albumin binding affinity. The aim of the present study was to understand and quantify this effect.

Methods: Quenching of intrinsic fluorescence of human serum albumin was used to monitor the competitive binding of antidiabetic drugs (gliclazide, glimepiride, glipizide and repaglinide) and bilirubin/hemin/chloride ions.

Results and conclusions: Bilirubin and hemin were bound at site I and site II in human serum albumin with association constants of the order of 105. The presence of bilirubin decreased the binding affinity of all the antidiabetic drugs. In the presence of hemin, the binding of gliclazide and glimepiride increased significantly, whereas that of glipizide and repaglinide decreased. The presence of chloride ions decreased the association constants of all drugs except glimepiride. More than 20% increase in the percentage of free drug was observed for gliclazide in the presence of bilirubin and for repaglinide in the presence of bilirubin and hemin. A large decrease was also observed in the percentage of free gliclazide in the presence of hemin, and free glimepiride in the presence of hemin and chloride ions. Competitive binding mechanism has also been proposed. Significant changes (increase/decrease) in the availability of free pharmacologically active antidiabetic drugs, observed in some cases, can result in fluctuations in the blood glucose level of diabetic patients. The effect, which varied with the nature of the drug and the competing substance, was relatively large for gliclazide and repaglinide compared to other drugs.

Keywords: antidiabetic drugs; bilirubin; fluorescence; hemin; human serum albumin


  • 1.

    Brodersen R. Competitive binding of bilirubin and drugs to human serum albumin studied by enzymatic oxidation. J Clin Invest 1974;54:1353–64.CrossrefPubMedGoogle Scholar

  • 2.

    Ahlfors CE. Competitive interaction of biliverdin and bilirubin only at the primary bilirubin binding site on human albumin. Anal Biochem 1981;110:295–307.PubMedCrossrefGoogle Scholar

  • 3.

    Wilting J, van der Giesen WF, Janssen LH. The effect of chloride ion on the binding of warfarin to albumin as a function of pH. Biochem Pharmacol 1981;30:1025–31.CrossrefGoogle Scholar

  • 4.

    Shin HS, Jung YS, Rim H. Relationship of serum bilirubin concentration to kidney function and 24-hour urine protein in Korean adults. BMC Nephrol 2011;12:Article no. 29.Web of ScienceCrossrefPubMedGoogle Scholar

  • 5.

    Rigato I, Ostrow JD, Tiribelli C. Bilirubin and the risk of common non-hepatic diseases. Trends Mol Med 2005;11:277–83.PubMedCrossrefGoogle Scholar

  • 6.

    Hunt SC, Kronenberg F, Eckfeldt JH, Hopkins PN, Myers RH, Heiss G. Association of plasma bilirubin with coronary heart disease and segregation of bilirubin as a major gene trait: the NHLBI family heart study. Atheroscerosis 2001;154:747–54.Google Scholar

  • 7.

    Brodersen R, Robertson A. Ceftriaxone binding to human serum albumin: competition with bilirubin. Mol Pharmacol 1989;36:478–83.PubMedGoogle Scholar

  • 8.

    Silva D, Cortez CM, Louro SR. Quenching of the intrinsic fluorescence of bovine serum albumin by chlorpromazine and hemin. Braz J Med Biol Res 2004;37:963–68.PubMedGoogle Scholar

  • 9.

    Goldstein L, Teng ZP, Zeserson E, Patel M, Regan RF. Hemin induces an iron-dependent, oxidative injury to human neuron-like cells. J Neurosci Res 2003;73:113–21.Google Scholar

  • 10.

    Ikarlyama Y, Suzuki S, Aizawa M. Luminescence immunoassay of human serum albumin with hemin as labeling catalyst. Anal Chem 1982;54:1126–29.CrossrefGoogle Scholar

  • 11.

    Schambelan M, Sebastian A, Rector FC Jr. Mineralocorticoid-resistant renal hyperkalemia without salt wasting (type II pseudohypoaldosteronism): role of increased renal chloride reabsorption. Kidney Int 1981;19: 716–27.CrossrefGoogle Scholar

  • 12.

    Lacowicz JR. Principles of fluorescence spectroscopy, 3rd ed. New York, NY, USA: Springer, 2006.Google Scholar

  • 13.

    Seedher N, Kanojia M. Reversible binding of antidiabetic drugs, repaglinide and gliclazide, with human serum albumin. Chem Biol Drug Des 2008;72:290–6.CrossrefWeb of SciencePubMedGoogle Scholar

  • 14.

    Seedher N, Kanojia M. Mechanism of interaction of hypoglycemic agents glimepiride and glipizide with human serum albumin. Cent Eur J Chem 2009;7:96–104.CrossrefWeb of ScienceGoogle Scholar

  • 15.

    Ahlfors CE. Measurement of plasma unbound unconjugated bilirubin. Anal Biochem 2000;279:130–5.Google Scholar

  • 16.

    Amisha Kamal JK, Behere D. Binding of heme to human serum albumin: steady state fluorescence, circular dichroism and optical difference spectroscopic studies. Indian J Biochem Biophys 2005;42:7–12.Google Scholar

  • 17.

    Weisiger RA, Ostrow JD, Koehler RK, Webster CC, Mukerjee P, Pascolo L, et al. Affinity of human serum albumin for bilirubin varies with albumin concentration and buffer composition. Results of a novel ultrafiltration method. J Biol Chem 2001;276:29953–60.Google Scholar

About the article

Corresponding author: Neelam Seedher, Department of Chemistry, Panjab University, Chandigarh 160014, India, Phone: +91-0172-2534431 (O), +91-0172-2661025 (R)

Received: 2012-12-31

Accepted: 2013-03-04

Published Online: 2013-04-04

Published in Print: 2013-06-01

Citation Information: Drug Metabolism and Drug Interactions, Volume 28, Issue 2, Pages 107–114, ISSN (Online) 2191-0162, ISSN (Print) 0792-5077, DOI: https://doi.org/10.1515/dmdi-2012-0044.

Export Citation

©2013 by Walter de Gruyter Berlin Boston.Get Permission

Comments (0)

Please log in or register to comment.
Log in